Abstract
Kidney and cardiovascular diseases are highly prevalent among patients with Type 1 diabetes. To date, no randomised clinical trial has reported on the impact of novel cardio-kidney-metabolic (CKM) therapies (GLP- 1RA and SGLT2i) on kidney function in this population. We investigated a large US database to determine whether CKM therapies were used, beneficial and safe among patients with Type 1 diabetes and chronic kidney disease (CKD).
Materials and Methods: Adults with Type 1 diabetes in Optum’s de-identified Market Clarity database, consisting of claims and electronic medical records data, between January 1, 2016, and December 31, 2023, were included. Patients who had their first CKM therapy prescription during the study period were propensity score-matched to those not on CKM therapy. The 253 patients with sufficient data to assess changes in urinary albumin-to-creatinine ratio (UACR) were included in the analyses. Rates of hypoglycaemia and diabetic ketoacidosis were also assessed.
Results: CKM therapy was used by more than 10 % of the patients with Type 1 diabetes and CKD. At baseline, average age was 52 years, HbA1c 8.1%, eGFR 77 mL/min/1.73 m2. UACR median was 60.8 mg/g. Time to 30% or more UACR reduction was shorter among patients on CKM therapy versus controls [HR 0.76 (CI 0.61–0.95), p = 0.0158]. Rates of hypoglycaemia and diabetic ketoacidosis were not increased among patients on CKM therapy.
Conclusions: CKM therapy was frequently used in patients with Type 1 diabetes and CKD, associated with UACR reduction and safe. These clinically relevant data warrant confirmation in randomised clinical trials.
Стаття надійшла в редакцію: 07.01.2026 /Received: 07.01.2026
Після доопрацювання: 26.02.2026/Revised: 26.02.2026
Прийнято до друку: 26.02.2026/Accepted: 26.02.2026
References
1. Nuffield Department of Population Health Renal Studies G and Consortium SiM-AC-RT, “Impact of Diabetes on the Effects of Sodium Glucose Co-Transporter-2 Inhibitors on Kidney Outcomes: Collaborative Meta-Analysis of Large Placebo-Controlled Trials,” Lancet 400 (2022): 1788–1801.
2. V. Perkovic, K. R. Tuttle, P. Rossing, et al., “Effects of Semaglutide on Chronic Kidney Disease in Patients With Type 2 Diabetes,” New England Journal of Medicine 391 (2024): 109–121.
3. G. L. Bakris, R. Agarwal, S. D. Anker, et al., “Effect of Finerenone on Chronic Kidney Disease Outcomes in Type 2 Diabetes,” New England Journal of Medicine 383 (2020): 2219–2229.
4. American Diabetes Association, “Pharmacologic Approaches to Glycemic Treatment: Standards of Care in Diabetes-2025,” Diabetes Care 48 (2025): S181–S206.
5.Kidney Disease: Improving Global Outcomes CKDWG, “KDIGO 2024 Clinical Practice Guideline for the Evaluation and Management of Chronic Kidney Disease,” Kidney International 105 (2024): S117–S314.
6. I. H. de Boer, M. L. Caramori, J. C. N. Chan, et al., “GLP-1 Receptor Agonists and Other Incretin Mimetics for Diabetes and Chronic Kidney Disease—A KDIGO Commentary,” Kidney International 107 (2025): 767–771.
7. Group E-KC, “Impact of Primary Kidney Disease on the Effects of Empagliflozin in Patients With Chronic Kidney Disease: Secondary Analyses of the EMPA-KIDNEY Trial,” Lancet Diabetes and Endocri- nology 12 (2024): 51–60.
8. P. H. Groop, P. Dandona, M. Phillip, et al., “Effect of Dapagliflozin as an Adjunct to Insulin Over 52Weeks in Individuals With Type 1 Diabetes: Post-Hoc Renal Analysis of the DEPICT Randomised Controlled Trials,” Lancet Diabetes and Endocrinology 8 (2020): 845–854.
9. D. H. van Raalte, P. Bjornstad, F. Persson, et al., “The Impact of Sotagliflozin on Renal Function, Albuminuria, Blood Pressure, and Hematocrit in Adults With Type 1 Diabetes,” Diabetes Care 42 (2019): 1921–1929.
10. H. J. L. Heerspink, A. L. Birkenfeld, D. Z. I. Cherney, et al., “Rationale and Design of a Randomised Phase III Registration Trial Investigating Finerenone in Participants With Type 1 Diabetes and Chronic Kidney Disease: The FINE-ONE Trial,” Diabetes Research and Clinical Practice 204 (2023): 110908.
11. H. J. L. C. Heerspink, A. L. Birkenfekd, D. Z. I. Cherney, et al., “Fi- nerenone in Type 1 Diabetes and Chronic Kidney Disease,” N Engl J Med 394 (2026): 947–957.
12. S. K. Garg, G. Kaur, D. Renner, et al., “Cardiovascular and Renal Biomarkers in Overweight and Obese Adults With Type 1 Diabetes Treated With Tirzepatide for 21 Months,” Diabetes Technology & Therapeutics 27 (2025): 152–160.
13. M. Anson, S. S. Zhao, P. Austin, G. H. Ibarburu, R. A. Malik, and U. Alam, “SGLT2i and GLP-1 RA Therapy in Type 1 Diabetes and Reno-Vascular Outcomes: A Real-World Study,” Diabetologia 66 (2023): 1869–1881.
14. M. Duran-Martinez, S. Azriel, V. K. Doulatram-Gamgaram, et al., “Real-World Safety and Effectiveness of Dapagliflozin in People Living With Type 1 Diabetes in Spain: The Dapa-ON Multicenter Retrospective Study,” Diabetes & Metabolism 50 (2024): 101501.
15. P. Li, Z. Li, E. Staton, et al., “GLP-1 Receptor Agonist and SGLT2 Inhibitor Prescribing in People With Type 1 Diabetes,” JAMA 332 (2024): 1667–1669.
16. M. Klompas, E. Eggleston, J. McVetta, R. Lazarus, L. Li, and R. Platt, “Automated Detection and Classification of Type 1 Versus Type 2 Diabetes Using Electronic Health Record Data,” Diabetes Care 36 (2013): 914–921.
17. E. B. Schroeder, W. T. Donahoo, G. K. Goodrich, and M. A. Raebel, “Validation of an Algorithm for Identifying Type 1 Diabetes in Adults Based on Electronic Health Record Data,” Pharmacoepidemiology and Drug Safety 27 (2018): 1053–1059.
18. L. A. Inker, N. D. Eneanya, J. Coresh, et al., “New Creatinine- and Cystatin C-Based Equations to Estimate GFR Without Race,” New En- gland Journal of Medicine 385 (2021): 1737–1749.
19. M. Charlson, T. P. Szatrowski, J. Peterson, and J. Gold, “Validation of a Combined Comorbidity Index,” Journal of Clinical Epidemiology 47 (1994): 1245–1251.
20. D. K. McGuire, W. J. Shih, F. Cosentino, et al., “Association of SGLT2 Inhibitors With Cardiovascular and Kidney Outcomes in Patients With Type 2 Diabetes: A Meta-Analysis,” JAMA Cardiology 6 (2021): 148–158.
21. B. L. Neuen, R. A. Fletcher, L. Heath, et al., “Cardiovascular, Kidney, and Safety Outcomes With GLP-1 Receptor Agonists Alone and in Combination With SGLT2 Inhibitors in Type 2 Diabetes: A Systematic Review and Meta-Analysis,” Circulation 150 (2024): 1781–1790.
22. R. Agarwal, G. Filippatos, B. Pitt, et al., “Cardiovascular and Kidney Outcomes With Finerenone in Patients With Type 2 Diabetes and Chronic Kidney Disease: The FIDELITY Pooled Analysis,” European Heart Journal 43 (2022): 474–484.
23. J. Coresh, H. J. L. Heerspink, Y. Sang, et al., “Change in Albuminuria and Subsequent Risk of End-Stage Kidney Disease: An Individual Participant-Level Consortium Meta-Analysis of Observational Studies,” Lancet Diabetes & Endocrinology 7 (2019): 115–127.
24. H. J. L. Heerspink, J. Coresh, R. T. Gansevoort, and L. A. Inker, “Change in Albuminuria as a Surrogate Endpoint in Chronic Kidney Disease - Authors' Reply,” Lancet Diabetes and Endocrinology 7 (2019): 336 –337.
25. H. J. L. Heerspink, T. Greene, H. Tighiouart, et al., “Change in Albuminuria as a Surrogate Endpoint for Progression of Kidney Disease: A Meta-Analysis of Treatment Effects in Randomised Clinical Trials,” Lancet Diabetes & Endocrinology 7 (2019): 128–139.
26. L. A. Inker, M. E. Grams, H. Guethmundsdottir, et al., “Clinical Trial Considerations in Developing Treatments for Early Stages of Common, Chronic Kidney Diseases: A Scientific Workshop Cosponsored by the National Kidney Foundation and the US Food and Drug Administration,” American Journal of Kidney Diseases 80 (2022): 513–526.
27. N. Jongs, T. Greene, G. M. Chertow, et al., “Effect of Dapagliflozin on Urinary Albumin Excretion in Patients With Chronic Kidney Disease With and Without Type 2 Diabetes: A Prespecified Analysis From the DAPA-CKD Trial,” Lancet Diabetes & Endocrinology 9 (2021): 755–766.
28. L. Kugathasan, Y. Aronson, V. S. Sridhar, et al., “Advancing Kidney Protection in Type 1 Diabetes: Insights From Emerging Therapies in Type 2 Diabetes and Chronic Kidney Disease,” Expert Review of Clinical Immunology 21 (2025): 1113–1134.
29. F. H. Mahmud, P. Bjornstad, C. Clarson, et al., “Adjunct-To-Insulin Therapy Using SGLT2 Inhibitors in Youth With Type 1 Diabetes: A Randomized Controlled Trial,” Nature Medicine 31 (2025): 2317–2324.
30.V. N. Shah, H. K. Akturk, D. Kruger, et al., “Semaglutide in Adults With Type 1 Diabetes and Obesity,” NEJM Evidence 4 (2025): EVIDoa2500173.
31. A. R. Pandey, E. Repetto, C. Perkins, P. Rossing, and M. L. Caramori, “Association Between Off-Label Use of Cardio-Kidney-Metabolic Therapies and Risk of Cardiovascular Events in Type 1 Diabetes: A Real- World Evidence Study,” Diabetes, Obesity & Metabolism (2026).
32. G. S. Carls, E. Tuttle, R. D. Tan, et al., “Understanding the Gap Be- tween Efficacy in Randomized Controlled Trials and Effectiveness in Real-World Use of GLP-1 RA and DPP-4 Therapies in Patients With Type 2 Diabetes,” Diabetes Care 40 (2017): 1469–1478.
33. D. Z. I. Cherney, N. Belmar, P. Bjornstad, et al., “Rationale, Design and Baseline Characteristics of REMODEL, a Mechanism-Of-Action Trial With Semaglutide in People With Type 2 Diabetes and Chronic Kidney Disease,” Nephrology, Dialysis, Transplantation 40 (2025): 2182–2192.
34. V. S. Sridhar, A. Odutayo, S. Garg, et al., “Efficacy and Safety of Sotagliflozin in Patients With Type 1 Diabetes and CKD,” Journal of the American Society of Nephrology 36 (2025): 890–900.
35. E. B. Stougaard, M. R. Andersen, J. I. Bagger, et al., “The Steno 1 Study: Multifactorial Intervention to Reduce Cardiovascular Disease in Type 1 Diabetes-Rationale and Protocol of the Prospective, Random- ized, Open-Labelled Multicentre Study,” Diabetes, Obesity & Metabolism 27 (2025): 5432–5443.
This work is licensed under a Creative Commons Attribution-ShareAlike 4.0 International License.